With drug developers and manufacturers facing closer scrutiny on product quality than ever before, it’s time to make the most of evolving process analytical technology to design robust and cost-effective control strategies and understand more about your biopharmaceutical products.  

The likes of Bristol Myers Squibb, BMS, Vertex, Moderna, Sanofi and Novo Nordisk and more are uniting this December at the 2^nd PAT & Real Time Quality Summit to revolutionize real-time quality strategies across a wide range of novel modality applications, and share advances in machine learning that are making real-time control and diversion a reality.

Whilst the sector still battles with justifying investment and integration, the summit demonstrates tangible return on investment for process analytical technology in drug development and GMP environments, through increased yield, inline and online monitoring, predictive modelling, and accelerated speed to market.  

Join 60+ PAT experts, including process development, analytical development, MSAT directors, and chemometricians; at the one and only end-to-end playbook for the successful advancement, integration, and adoption of process analytical technology in highly regulated pharmaceutical environments.